Family Search for PF09755 (DUF2046)

PF09755.9 hits 2 sequences in PaperBLAST's database above the trusted cutoff. Showing all hits. Or show only hits to curated sequences or try another family.

XP_006514339 coiled-coil domain-containing protein 6 isoform X1 from Mus musculus
Aligns to 25:330 / 412 (74.3%), covers 94.7% of PF09755, 497.7 bits

• Ccdc6 knock-in mice develop thyroid hyperplasia associated to an enhanced CREB1 activity.
  Leone, Oncotarget 2015
  • GeneRIF: Ccdc6-ex2 knock-in mice developed thyroid hyperplasia associated with an enhanced CREB1 activity and an increased expression of the CREB-1 regulated genes.
• Critical role of CCDC6 in the neoplastic growth of testicular germ cell tumors.
  Staibano, BMC cancer 2013
  • GeneRIF: the loss of CCDC6 could aid the spermatogonial cells to be part of a pro-survival pathway that helps to evade the toxic effects of endogenous oxidants and contributes to testicular neoplastic growth.

CCDC6_HUMAN / Q16204 Coiled-coil domain-containing protein 6; Papillary thyroid carcinoma-encoded protein; Protein H4 from Homo sapiens (Human) (see paper)
NP_005427 coiled-coil domain-containing protein 6 from Homo sapiens
Aligns to 42:337 / 474 (62.4%), covers 94.4% of PF09755, 490.2 bits

• MicroRNA-146b-5p as an oncomiR promotes papillary thyroid carcinoma development by targeting CCDC6.
  Jia, Cancer letters 2019 (PubMed)
  • GeneRIF: Results demonstrate that CCDC6 is a direct target of miR-146b which downregulates CCDC6 expression in papillary thyroid cancer (PTC). Also, CCDC6 expression correlates with clinicopathological parameters and exerts significant diagnostic and prognostic value in patients with PTC.
• CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
  Morra, Journal of experimental & clinical cancer research : CR 2019
  • GeneRIF: The identification of two clusters of patients based on CCDC6 and USP7 expession can possibly indicate the use of PARP-inhibitor drugs.
• Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
  Morra, Lung cancer (Amsterdam, Netherlands) 2019 (PubMed)
  • GeneRIF: we propose CCDC6 as a biomarker of drugs sensitivity for MPMs. In case of MPMs expressing low levels of CCDC6 the addition of olaparib to cisplatinum and pemetrexed is expected to be highly beneficial. In case of MPMs expressing normal CCDC6 levels the sensitivity to olaparib can be restored by the addition of P5091.
• Genome sequencing for nonsmall-cell lung cancer identifies a basis for nintedanib sensitivity.
  Takeda, Annals of oncology : official journal of the European Society for Medical Oncology 2016 (PubMed)
  • GeneRIF: Our findings nevertheless suggest that CCDC6-RET fusions identified by multiplex testing are potential targets for nintedanib therapy.
• Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein.
  Wang, Cancer letters 2016
  • GeneRIF: FGFR inhibitors, particularly BGJ398, are therapeutic options for cholangiocarcinoma patients harboring FGFR2-CCDC6 fusions.
• New therapeutic perspectives in CCDC6 deficient lung cancer cells.
  Morra, International journal of cancer 2015 (PubMed)
  • GeneRIF: CCDC6 levels provide valuable insight for OS.
• The cell cycle regulator CCDC6 is a key target of RNA-binding protein EWS.
  Duggimpudi, PloS one 2015
  • GeneRIF: Results show that RNA-binding protein EWS binds and regulates CCDC6 expression at RNA and protein levels.
• FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
  Morra, Oncotarget 2015
  • GeneRIF: we propose that the amount of CCDC6 protein in primary tumors, as reported in lung, may depend on the impairment of the CCDC6 turnover due to altered protein-protein interaction and post-translational modifications
• More
• dBMHCC: A comprehensive hepatocellular carcinoma (HCC) biomarker database provides a reliable prediction system for novel HCC phosphorylated biomarkers
  Chu, PloS one 2020
  • “...S k S cm 2289 Q13451 FKBP5 8.00 4.29 7175 P12270 TPR 7.40 4.26 8030 Q16204 CCDC6 6.00 4.69 83667 P58004 SESN2 6.00 4.53 55367 Q9HB75 PIDD1 6.00 4.53 64065 Q96FX8 PERP 6.00 4.53 55256 Q9BV57 ADI1 6.00 4.49 27430 Q9NZL9 MAT2B 6.00 4.49 2069 O14944...”
• Ginsenoside Rh2 activates α-catenin phosphorylation to inhibit lung cancer cell proliferation and invasion.
  Zhang, Experimental and therapeutic medicine 2020
  • “...1226.3796 3 S159 P35221 CTNNA1 Catenin -1 100693 5.95 R.TPEELDDSDFETEDFDVR.S 98 9.50E-09 1120.2859 2 S641 Q16204 CCDC6 Coiled-coil domain-containing protein 6 53429 6.87 K.LDQPVSAPPSPR.D 38 0.0045 712.4462 2 S240, S244 Q9UPQ0 LIMCH1 LIM and calponin homology domains-containing protein 1 122818 6.1 K.SPEPEATLTFPFLDK.M 52 0.0031 886.3337 2...”
• β-Catenin Knockdown Affects Mitochondrial Biogenesis and Lipid Metabolism in Breast Cancer Cells
  Vergara, Frontiers in physiology 2017
  • “...7 70.8 SAFB Scaffold attachment factor B1 Q15424 9 16.6 CCDC6 Coiled-coil domain-containing protein 6 Q16204 7 17.7 FSCN1 Fascin Q16658 16 41.2 LRRFIP1 Leucine-rich repeat flightless-interacting protein 1 Q32MZ4 10 17 MYH14 Myosin-14 Q7Z406 42 28 KTN1 Kinectin Q86UP2 46 41.9 NMD3 60S ribosomal export...”

Or search for genetic data about PF09755 in the Fitness Browser